What is the patent scope of US 11,389,447 (TMC278 long-acting nanoparticle HIV dosing)?
US 11,389,447 claims a specific long-acting parenteral dosing method for the HIV drug TMC278 (rilpivirine) (the compound name in the claims), where efficacy is tied to achieving patient plasma levels through a defined nanoparticle intramuscular or subcutaneous formulation. The claims combine (1) a drug identity and stereochemistry/salt options, (2) a nanoparticle engineering parameter set (poloxamer-coated particles with defined particle size), and (3) a dosing regimen and dosage amount tied to 4-week (monthly) intermittent dosing, plus (4) formulation composition windows and (5) broad excipient categories (buffering/isotonicity/preservatives).
Core independent claim (Claim 1) is a method claim, not a composition claim, but it functionally and structurally defines the administered product and regimen. Every dependent claim narrows within that product-regimen framework.
Claim 1 key elements (binding scope):
- Purpose/functional efficacy: “producing blood plasma levels of TMC278 … sufficient to treat an HIV infection” in an HIV-infected patient.
- Route: administered intramuscularly or subcutaneously.
- Drug form: TMC278 or a salt, stereoisomer, or stereoisomeric mixture.
- Carrier/form: aqueous suspension comprising nanoparticles of TMC278 (or salt/stereoisomer forms).
- Nanoparticle surface: particles have poloxamer adsorbed onto the surfaces.
- Particle size constraint: average effective particle size below about 1000 nm.
- Dosing frequency/regimen: administered intermittently once every four weeks or once every month.
- Dose-to-exposure linkage: amount is effective to produce plasma levels “sufficient … during the time interval.”
What does Claim 1 cover operationally? (product + regimen + exposure)
A. Product definition that drives claim infringement
The claimed product is an aqueous suspension of drug nanoparticles with:
- TMC278 nanoparticles (or specified salt/stereoisomer variants)
- poloxamer adsorbed to particle surfaces
- average effective particle size < 1000 nm
The claim does not require the suspension to be identical to a commercial product, but it requires those structural/functional attributes in the administered material.
B. Regimen definition that drives method infringement
The method requires:
- injection route: intramuscular or subcutaneous
- schedule: every four weeks / once per month
- duration of each exposure interval: plasma levels sufficient “during the time interval” meaning the dose must be designed for sustained therapeutic concentrations until the next administration.
C. Exposure linkage
Claim 1 is drafted so that infringement can be assessed via:
- Whether the administered dose produces plasma levels “sufficient to treat” over the dosing interval.
- This elevates the importance of pharmacokinetic performance, even though the claim also includes dosage and formulation parameters through dependent claims.
How do the dependent claims narrow the scope?
1) Dose amount windows (Claims 2, 3, 7, 13)
- Claim 2: dose calculated as ~5 mg/day to ~50 mg/day
- Claim 3: subset ~10 mg/day to ~25 mg/day
- Claim 7: monthly dose corresponds to:
- 150 mg to 1500 mg
- or 30 mg to 300 mg
- or 300 mg (single value option)
- Claim 13: integrates:
- dose basis ~10 mg/day to ~25 mg/day
- E-isomer of base form
- poloxamer 338
Business implication: the patent’s enforceable core is tied to mid-to-high monthly drug loads expressed both as daily-equivalent basis (5-50 mg/day, then 10-25 mg/day) and as monthly totals (multiple ranges including a discrete 300 mg option). Reformulation or dosing outside these ranges risks invalidity-by-narrowing or non-infringement-by-design.
2) Drug form specificity: base vs salt; E-isomer options (Claims 4, 9, 10)
- Claim 4: TMC278 is base or acid addition salt form.
- Claim 9: TMC278 is E-isomer of the base.
- Claim 10: TMC278 is E-isomer of the acid addition salt.
Business implication: if an infringer uses a non-E isomer, or a different salt class not captured by the claim language as “acid addition salt,” it may avoid these narrower dependent claims, but Claim 1 still covers “a stereoisomer … or stereoisomeric mixture,” so avoidance must be comprehensive.
3) Poloxamer identity (Claims 5, 13)
- Claim 5: poloxamer is poloxamer 338.
- Claim 13: locks poloxamer 338 and E-isomer with 10-25 mg/day basis.
Business implication: poloxamer 338 is a direct narrowing fallback position. Claim 1 does not limit to poloxamer 338, only “poloxamer,” so a competitor using another poloxamer could still face Claim 1 exposure unless other parameters differ.
4) Particle size narrowing (Claims 6, 14-23)
- Claim 6: if poloxamer 338 is used, particle size is ~50 nm to ~1000 nm.
- Claim 14: 150 nm to 220 nm
- Claim 20: 50 nm to 400 nm
- Claim 21: 50 nm to 250 nm
- Claim 22: about 400 nm (single point)
- Claim 23: about 200 nm (single point)
Business implication: the patent has multiple “guardrails” at specific size bands and discrete values (200 nm and 400 nm). That pattern is consistent with a formulation development target and gives the patentee multiple dependent-claim anchors.
5) Weight ratio of drug to poloxamer (Claims 15, 16)
- Claim 15: TMC278 : poloxamer w/w = 1:2 to 20:1
- Claim 16: specific w/w ratios:
Business implication: this is a classic formulation narrowing axis. If an infringer’s nanoparticles use a different loading ratio outside these windows, dependent claims may not read even if Claim 1 arguably could.
6) Injection frequency and route specifics (Claims 17-19)
- Claim 17: aqueous suspension administered by intramuscular injection
- Claim 18: intramuscular once every four weeks
- Claim 19: intramuscular once every month
Business implication: Claim 1 covers IM or SC. These dependent claims harden enforceability for IM dosing on monthly schedules.
7) Full formulation composition ranges with excipient families (Claim 8, Claims 11-12)
-
Claim 8 defines weight percentages (based on total composition volume):
- TMC278: 3% to 50%, or 10% to 40%, or 10% to 30%
- Poloxamer: 0.5% to 10%, or 0.5% to 2%
- Buffering agent: 0% to 10%, or 0% to 5%, or 0% to 2%, or 0% to 1%
- Isotonizing agent: 0% to 10%, or 0% to 6%
- Preservatives: 0% to 2%
- Water for injection: q.s. ad 100%
-
Claim 11: buffering agent can be one or more from a long enumerated list including:
- organic acids (tartaric, maleic, lactic, citric, acetic, gluconic-related, succinic, benzoic)
- salts (sodium citrates, sodium acetate, benzoate sodium, phosphates)
- amino-alcohols/bases (tromethamine, triethanolamine, monoethanolamine)
- inorganic acids/bases (hydrochloric, hydrogen bromide, sodium hydroxide)
- EDTA
- and mixtures
-
Claim 12: isotonizing agent can be:
- sugars (glucose, dextrose, sucrose, fructose, trehalose, lactose)
- polyhydric sugars and sugar alcohols (polyhydric sugars; trihydric or higher sugar alcohols)
- glycerin, erythritol
- arabitol, xylitol, sorbitol, mannitol
- sodium chloride or sodium sulfate
Business implication: Claim 8 plus Claims 11-12 provide broad formulation latitude while still constraining the drug, poloxamer, and particle size axes. The excipient language is extensive enough that “formulation redesign” via different buffers/isotonics is unlikely to create freedom-to-operate unless composition values move outside the recited ranges.
Claim set map (what’s enforceable if you change one variable)
| Variable |
Claim anchor |
Scope effect if changed |
| Route |
Claim 1 (IM or SC); Claims 17-19 (IM monthly) |
Switching to a route not covered by dependent claims may still fall under Claim 1 if route remains IM or SC. |
| Dosing frequency |
Claim 1 (once every 4 weeks / month); Claims 18-19 (IM) |
Deviating from monthly interval targets dependent claims but may still risk Claim 1 if schedule stays within monthly pattern. |
| Drug identity |
Claim 1 (TMC278 or salt/stereoisomer); Claim 4 (base or acid addition salt); Claims 9-10 (E-isomer) |
Different stereoisomer strategy could avoid dependent claims 9-10, but Claim 1 still includes “stereoisomeric mixture.” |
| Particle size |
Claim 1 (<1000 nm); Claims 6, 14, 20-23 |
Changing nanoparticle size can avoid many dependent claims, but Claim 1 still captures anything below 1000 nm. |
| Poloxamer surface |
Claim 1 (poloxamer adsorbed); Claim 5 (poloxamer 338) |
Using a non-poloxamer stabilizer can be a primary design-around if it breaks “poloxamer adsorbed” element. |
| Drug:poloxamer ratio |
Claims 15-16 |
Changing weight ratio outside 1:2 to 20:1 avoids dependent ratios but does not automatically avoid Claim 1 unless other elements still satisfy. |
| Formulation composition % |
Claim 8 |
Moving drug or excipient percent outside listed ranges can avoid Claim 8 dependent claim reading, but Claim 1 remains tied to nanoparticle and regimen. |
| Dose amount |
Claims 2, 3, 7, 13 |
Monthly exposure strategy outside the mg/day and monthly ranges reduces the chance of reading dependent claims. Claim 1 still includes “effective to produce blood plasma levels,” which can be harder to control without PK confirmation. |
What is the likely patent landscape posture for this specific claim family?
Based solely on the claim set provided, US 11,389,447 is best characterized as a formulation-and-regimen specific “product-to-exposure” method patent rather than a broad therapeutic class claim. The landscape posture in practice is:
-
Nanoparticle formulation and excipient ranges are engineered for defensibility. Multiple dependent claims capture:
- poloxamer 338,
- specific particle size bands and discrete points (200 nm, 400 nm),
- drug-to-poloxamer weight ratios,
- and specific monthly dose equivalences.
-
Regimen is hard-coded into the enforceable core. Monthly administration appears across independent claim and IM-specific dependent claims, which is a strong hook against challenges framed around dosing schedule.
-
The patent is written to preserve infringement through multiple claim paths. Even if an accused infringer misses the exact particle size band, they may still land within the broader “< 1000 nm” requirement and still satisfy the method regimen conditions.
-
The excipient enumeration increases robustness. Buffer and tonicity ingredient lists plus broad ranges reduce the chance of clean design-around by excipient substitution, unless the formulation is moved outside the defined concentration windows.
Freedom-to-operate vectors (practical impact of the claim drafting)
The claim drafting implies the highest-risk infringement scenarios involve products that match the following triad simultaneously:
- Nanoparticles of TMC278 (<1000 nm) with poloxamer adsorbed
- Aqueous suspension injectable IM/SC
- Monthly (once every four weeks/month) dosing engineered for sustained plasma exposure
Even if a competitor changes excipient chemistry within buffer/isotonic families, they still face risk if nanoparticle-poloxamer size and dosing regimen are unchanged.
Key Takeaways
- US 11,389,447 claims a monthly long-acting method for delivering TMC278 via aqueous poloxamer-coated nanoparticles with average effective particle size < 1000 nm, administered IM or SC.
- The patent’s scope is anchored by (i) poloxamer adsorption on nanoparticles, (ii) particle size, and (iii) monthly dosing tied to therapeutic plasma levels.
- Dependent claims stack defensibility via (a) E-isomer and acid salt options, (b) poloxamer 338, (c) multiple particle size bands and discrete sizes (200 nm, 400 nm), (d) specific drug-to-poloxamer weight ratios, and (e) detailed composition ranges for drug and excipients.
- In a landscape sense, the strongest design-around levers are the ones that break poloxamer-coated nanoparticle requirements or the monthly dosing + sustained exposure relationship. Changing buffers or tonicity alone is unlikely to remove exposure if core nanoparticle and regimen elements remain.
FAQs
1) What is the main infringement hook in US 11,389,447?
Monthly administration of IM or SC injections of an aqueous suspension of TMC278 nanoparticles with poloxamer adsorbed and average effective particle size < 1000 nm, where the dose produces therapeutic plasma levels over the dosing interval.
2) Does the patent require poloxamer 338?
No. Claim 1 requires “poloxamer” adsorbed to nanoparticle surfaces. Poloxamer 338 appears in dependent Claim 5 and in a combined dependent claim (Claim 13).
3) Which particle size ranges are specifically claimed?
Independent Claim 1 captures < about 1000 nm. Dependent claims add ~50-1000 nm (with poloxamer 338), 150-220 nm, 50-400 nm, 50-250 nm, plus discrete ~200 nm and ~400 nm.
4) How is dosing specified?
The method requires intermittent dosing once every four weeks or once every month. Dependent claims quantify dose using mg/day equivalence and monthly dose ranges, including 150-1500 mg, 30-300 mg, and 300 mg monthly options.
5) Do excipient choices create clear design-around space?
The patent lists many buffering and tonicity agents and provides broad ranges in Claim 8. Substituting buffers or isotonic agents is unlikely to avoid infringement if the product still matches the core nanoparticle-poloxamer and monthly dosing requirements.
References
[1] United States Patent No. 11,389,447. “Method for producing blood plasma levels of TMC278 sufficient to treat an HIV infection in an HIV-infected patient.” Claims 1-23 (as provided).
